Softox Solutions AS ("SoftOx") is pleased to announce that it today has entered
into a financing facility with the global investment fund Long State Investments
Limited ("Long State") for a total commitment of NOK 50 million over a 24-month
period, with the option to extend the facility to NOK 80 million over 36 months.


Under the facility, Long State has granted SoftOx an equity line of credit,
allowing SoftOx to call funds against the issuance of new shares on a flexible
basis in accordance with market conditions. SoftOx is not obligated to utilize
the facility and will only access the program subject to prevailing market
conditions, retaining full discretion over the timing, minimum subscription
price, and amount of each drawdown. 

The share placements will be executed by the board under the board authorization
granted by the general meeting June 27 2025. The subscription price for the
shares will be a function of the VWAP of SoftOx's shares during a pricing
period, upon which pricing and volume will be calculated and announced. 

"This facility puts SoftOx in a position of maximum financial flexibility,
ensuring we can access capital to support our priorities while maintaining
control over both timing and pricing," said Ingrid Juven, Chief Financial
Officer of SoftOx. 

As commission for the guarantee facility, Long State shall receive an
implementation fee of up to 30 million shares in SoftOx, plus a market-based
cash consideration equal to a percentage of the actual invested amount, and a
one-time grant of 60 million warrants with the right to subscribe for 60 million
shares in SoftOx at a subscription price (strike) of NOK 0,1506. The warrant
compensation will be resolved by a forthcoming extraordinary general meeting,
or, if preferred by SoftOx, its cash-value equivalent at their time of grant. 

"We see this as a relevant, flexible, and effective tool under the current
market conditions for emerging life science companies," said Ulrik Spork,
Chairman of SoftOx. "It gives us important certainty around capital formation as
we move into the execution phase of our clinical trials, ensuring we have
resources available when we need them." 

The facility effectively serves as a robust guarantee for SoftOx to conduct
share placements up to the committed amount, providing a reliable source of
capital. The facility provides SoftOx with an opportunity to tailor capital
raising according to its needs, while ensuring a stable financial platform for
further growth and development. The agreement does not restrict SoftOx from
seeking other equity or strategic financing alternatives and may be terminated
by SoftOx at any time without penalty. 

For further information, please contact:  

Ulrik Spork, COB SoftOx Solutions AS, +45 31 38 83 87  
Ingrid Juven, CFO SoftOx Solutions AS, +47 918 76 165 

Mail: ir@soft-ox.com  

About SoftOx Solutions AS:  
SoftOx Solutions AS (ticker: SOFTX) is a clinical-stage pharmaceutical company
listed on Euronext Growth Oslo. The company is developing highly effective
pan-antimicrobial pharmaceuticals targeting bacteria, viruses, and fungi. The
technology is based on extensive research and development in partnership with
leading Nordic research institutes. 

About Longstate